JP2017515792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515792A5 JP2017515792A5 JP2016555508A JP2016555508A JP2017515792A5 JP 2017515792 A5 JP2017515792 A5 JP 2017515792A5 JP 2016555508 A JP2016555508 A JP 2016555508A JP 2016555508 A JP2016555508 A JP 2016555508A JP 2017515792 A5 JP2017515792 A5 JP 2017515792A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 3
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 102000046828 human IL1RAP Human genes 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403875.6A GB201403875D0 (en) | 2014-03-05 | 2014-03-05 | Novel antibodies and uses thereof |
| GB1403875.6 | 2014-03-05 | ||
| PCT/GB2015/050647 WO2015132602A1 (en) | 2014-03-05 | 2015-03-05 | Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515792A JP2017515792A (ja) | 2017-06-15 |
| JP2017515792A5 true JP2017515792A5 (enExample) | 2018-04-12 |
| JP6396488B2 JP6396488B2 (ja) | 2018-09-26 |
Family
ID=50490826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555508A Active JP6396488B2 (ja) | 2014-03-05 | 2015-03-05 | 抗ヒトインターロイキン−１受容体アクセサリータンパク質（ｉｌ１ ｒａｐ）抗体およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9796783B2 (enExample) |
| EP (2) | EP3114145B1 (enExample) |
| JP (1) | JP6396488B2 (enExample) |
| KR (1) | KR102519196B1 (enExample) |
| CN (1) | CN106459195B (enExample) |
| AU (1) | AU2015225948B2 (enExample) |
| CA (1) | CA2941437C (enExample) |
| DK (2) | DK3293202T3 (enExample) |
| ES (2) | ES2646550T3 (enExample) |
| GB (1) | GB201403875D0 (enExample) |
| IL (1) | IL247459B (enExample) |
| LT (1) | LT3114145T (enExample) |
| MX (1) | MX360497B (enExample) |
| PL (1) | PL3114145T3 (enExample) |
| PT (1) | PT3114145T (enExample) |
| RU (1) | RU2710787C2 (enExample) |
| SG (1) | SG11201607322PA (enExample) |
| WO (1) | WO2015132602A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| DK3889172T3 (da) | 2014-02-10 | 2024-06-17 | Merck Patent Gmbh | Målrettet TGF-Beta-inhibering |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| WO2017059168A1 (en) * | 2015-10-01 | 2017-04-06 | Heat Biologics, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| US20180275121A1 (en) * | 2015-10-02 | 2018-09-27 | Tgr Biosciences Pty Ltd. | Analyte Detection with Multiple Substrates |
| JP2018534933A (ja) * | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| CA3084459A1 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| MX389083B (es) | 2016-12-01 | 2025-03-20 | Regeneron Pharma | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| MX2019009565A (es) | 2017-02-10 | 2020-02-24 | Regeneron Pharma | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet. |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| WO2018169922A2 (en) * | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| AU2018261890B2 (en) | 2017-05-05 | 2025-03-20 | Centre For Probe Development And Commercialization | IGF-1R monoclonal antibodies and uses thereof |
| AU2018261888B2 (en) | 2017-05-05 | 2022-06-30 | Centre For Probe Development And Commercialization | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
| US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| CN111246882A (zh) * | 2017-08-01 | 2020-06-05 | 希望之城 | 抗il1rap抗体 |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CN110759989B (zh) * | 2018-07-27 | 2021-08-17 | 中国人民解放军总医院 | IL-36γ作为动脉粥样硬化的标志物 |
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR20210099073A (ko) * | 2018-12-03 | 2021-08-11 | 퓨전 파마슈티칼즈 인크. | 방사성면역접합체와 체크포인트 억제제의 조합 요법 |
| AU2019405782A1 (en) | 2018-12-21 | 2021-06-17 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| JP2022521428A (ja) | 2019-02-25 | 2022-04-07 | ザ・ユニバーシティ・オブ・シカゴ | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 |
| CN110564848A (zh) * | 2019-04-15 | 2019-12-13 | 上海市同仁医院 | 白介素-36在制备结直肠癌预后产品中的应用 |
| WO2020215051A1 (en) * | 2019-04-19 | 2020-10-22 | Rpi Consulting Llc | Treatments for pregnancy-related conditions |
| KR20220026585A (ko) * | 2019-06-26 | 2022-03-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Il1rap 결합 단백질 |
| EP4013794A4 (en) | 2019-08-12 | 2023-11-22 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| JP2023521174A (ja) * | 2020-04-10 | 2023-05-23 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体 |
| BR112022022852A2 (pt) * | 2020-05-12 | 2022-12-20 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anticorpo st2 isolado ou um fragmento de ligação ao antígeno deste, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, fusão polipeptídica ou molécula multiespecífica, vetor viral, composição farmacêutica, métodos para determinar um nível de expressão de st2 em uma amostra de um sujeito e para uso no tratamento ou melhoria de doenças e condições relacionadas mediadas por il33/st2 em um sujeito que necessite |
| PE20231575A1 (es) * | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | Anticuerpos que se unen a il1rap y usos de estos |
| JP2024500920A (ja) | 2020-12-23 | 2024-01-10 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体 |
| CA3220913A1 (en) | 2021-05-21 | 2022-11-24 | Leo Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| CA3261336A1 (en) * | 2022-07-06 | 2024-01-11 | Bluefin Biomedicine, Inc. | METHODS OF TREATMENT FOR A DISEASE USING ANTI-IL1RAP ANTIBODIES AND ANTIBODY-DRUG CONJUGATIONS |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| KR20260007604A (ko) * | 2023-05-05 | 2026-01-14 | 오츠카 세이야쿠 가부시키가이샤 | 항-il1rap 항체 |
| WO2025126157A1 (en) * | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| WO2026022232A1 (en) | 2024-07-24 | 2026-01-29 | Almirall, S.A. | Il-1rap inhibitor for treating or preventing hidradenitis suppurativa |
| CN118772268B (zh) * | 2024-09-10 | 2025-02-11 | 山东第二医科大学 | 猴痘病毒a29l单克隆抗体、试剂盒及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| PE64396A1 (es) † | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US20030215453A1 (en) | 2002-05-14 | 2003-11-20 | Dedera Douglas A. | Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2426816T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| JP2010507366A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−１３受容体α１の抗体アンタゴニスト |
| EP2117303A4 (en) * | 2007-01-16 | 2011-06-08 | Abbott Lab | METHOD FOR THE TREATMENT OF DANDRUFFS |
| WO2009091547A1 (en) | 2008-01-15 | 2009-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2009120903A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) † | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| CN103608030A (zh) * | 2011-06-21 | 2014-02-26 | 昂科发克特公司 | 用于治疗和诊断癌症的组合物和方法 |
| CN103077969B (zh) | 2011-10-26 | 2016-03-30 | 中国科学院微电子研究所 | 一种mos器件及其制造方法 |
| WO2014113433A1 (en) | 2013-01-16 | 2014-07-24 | George Mason University | Binding domain mapping |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| JP2018534933A (ja) | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
| CA3084459A1 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| WO2018071910A2 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
-
2014
- 2014-03-05 GB GBGB1403875.6A patent/GB201403875D0/en not_active Ceased
-
2015
- 2015-03-05 PT PT157146036T patent/PT3114145T/pt unknown
- 2015-03-05 CN CN201580019206.1A patent/CN106459195B/zh active Active
- 2015-03-05 KR KR1020167027523A patent/KR102519196B1/ko active Active
- 2015-03-05 WO PCT/GB2015/050647 patent/WO2015132602A1/en not_active Ceased
- 2015-03-05 DK DK17185792.3T patent/DK3293202T3/da active
- 2015-03-05 JP JP2016555508A patent/JP6396488B2/ja active Active
- 2015-03-05 AU AU2015225948A patent/AU2015225948B2/en active Active
- 2015-03-05 LT LTEP15714603.6T patent/LT3114145T/lt unknown
- 2015-03-05 EP EP15714603.6A patent/EP3114145B1/en active Active
- 2015-03-05 DK DK15714603.6T patent/DK3114145T3/da active
- 2015-03-05 CA CA2941437A patent/CA2941437C/en active Active
- 2015-03-05 ES ES15714603.6T patent/ES2646550T3/es active Active
- 2015-03-05 ES ES17185792T patent/ES2861582T5/es active Active
- 2015-03-05 SG SG11201607322PA patent/SG11201607322PA/en unknown
- 2015-03-05 RU RU2016139068A patent/RU2710787C2/ru active
- 2015-03-05 EP EP17185792.3A patent/EP3293202B2/en active Active
- 2015-03-05 MX MX2016011414A patent/MX360497B/es active IP Right Grant
- 2015-03-05 PL PL15714603T patent/PL3114145T3/pl unknown
-
2016
- 2016-08-24 IL IL24745916A patent/IL247459B/en active IP Right Grant
- 2016-09-02 US US15/255,585 patent/US9796783B2/en active Active
-
2017
- 2017-09-18 US US15/707,593 patent/US10287357B2/en active Active
-
2019
- 2019-03-19 US US16/358,459 patent/US10752692B2/en active Active
-
2020
- 2020-07-16 US US16/930,631 patent/US11236172B2/en active Active
-
2021
- 2021-12-15 US US17/551,908 patent/US12398213B2/en active Active
-
2025
- 2025-07-14 US US19/267,857 patent/US20250340657A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515792A5 (enExample) | ||
| JP7118117B2 (ja) | 抗体－薬物コンジュゲートの選択的製造方法 | |
| JP7150820B2 (ja) | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート | |
| JP2022084608A (ja) | 抗ｔｒｏｐ２抗体－薬物コンジュゲート | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| JP2020536109A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2019107018A5 (enExample) | ||
| JP2017537620A5 (enExample) | ||
| JP2012529281A5 (enExample) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2015534577A5 (enExample) | ||
| JP2016505513A5 (enExample) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| RU2012137504A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| TW201620553A (zh) | 抗ｃｄ９８抗體－藥物結合物 | |
| JP2014518615A5 (enExample) | ||
| JP2010110329A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| JP2017530692A5 (enExample) | ||
| JP2017507936A5 (enExample) | ||
| JP2009526010A5 (enExample) | ||
| JP2013519364A5 (enExample) |